Ras inhibitor CAPRI enables neutrophil-like cells to chemotax through a higher-concentration range of gradients

Neutrophils sense and migrate through an enormous range of chemoattractant gradients through adaptation. Here, we reveal that in human neutrophils, calcium-promoted Ras inactivator (CAPRI) locally controls the GPCR-stimulated Ras adaptation. Human neutrophils lacking CAPRI (caprikd ) exhibit chemoat...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS Vol. 118; no. 43; pp. 1 - 12
Main Authors: Xu, Xuehua, Wen, Xi, Moosa, Amer, Bhimani, Smit, Jin, Tian
Format: Journal Article
Language:English
Published: United States National Academy of Sciences 26-10-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neutrophils sense and migrate through an enormous range of chemoattractant gradients through adaptation. Here, we reveal that in human neutrophils, calcium-promoted Ras inactivator (CAPRI) locally controls the GPCR-stimulated Ras adaptation. Human neutrophils lacking CAPRI (caprikd ) exhibit chemoattractant-induced, nonadaptive Ras activation; significantly increased phosphorylation of AKT, GSK-3α/3β, and cofilin; and excessive actin polymerization. caprikd cells display defective chemotaxis in response to high-concentration gradients but exhibit improved chemotaxis in low- or subsensitive-concentration gradients of various chemoattractants, as a result of their enhanced sensitivity. Taken together, our data reveal that CAPRI controls GPCR activation-mediated Ras adaptation and lowers the sensitivity of human neutrophils so that they are able to chemotax through a higher-concentration range of chemoattractant gradients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: X.X. designed research; X.X. contributed new reagents/analytic tools; X.X., X.W., A.M., and S.B. performed research and analyzed data; and X.X. and T.J. wrote the paper.
Edited by Philipp Niethammer, Memorial Sloan-Kettering Cancer Center, New York, NY and accepted by Editorial Board Member Carl F. Nathan August 19, 2021 (received for review February 6, 2020)
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.2002162118